{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:50:48Z","timestamp":1785466248946,"version":"3.56.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Wnt-catenin signaling antagonists sclerostin and dickkopf-related protein-1 (Dkk-1) inhibit bone formation and are involved in the pathogenesis of postmenopausal osteoporosis (PO). However, the association between sclerostin and Dkk-1 and bone mineral density (BMD) in women with PO remains unclear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>This study aimed to determine the association between sclerostin and Dkk-1 and BMD, bone microarchitecture, and bone strength in PO.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Trabecular bone specimens were obtained from the femoral heads of 76 Chinese women with PO who underwent hip arthroplasty for femoral neck fractures. Micro-computed tomography (Micro-CT) was used to assess the BMD and bone microarchitecture of the trabecular bone. Subsequently, a mechanical test was performed. Finally, sclerostin and Dkk-1 in the bone were measured by enzyme-linked immunosorbent (Elisa) assay. Serum ionized serum ionised calcium, propeptide of type 1 collagen, C-terminal \u03b2-telopeptide of type-1 collagen, sclerostin, and Dkk-1 were also detected.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Bone sclerostin was positively correlated with serum ionised calcium, serum sclerostin, BMD, bone volume\/tissue volume (BV\/TV), trabecular number (Tb.N), maximum compressive force, and yield strength (<jats:italic>r<\/jats:italic>\u2009=\u20090.32, 0.906, 0.355, 0.401, 0.329, 0.355, and 0.293, respectively, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) and negatively correlated with age and trabecular separation (Tb.Sp) (<jats:italic>r<\/jats:italic>\u2009=\u2009\u2212\u20090.755 and\u2009\u2212\u20090.503, respectively, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Bone Dkk-1 was positively correlated with serum ionised calcium, serum Dkk-1, BMD, BV\/TV, trabecular thickness, Tb.N, maximum compressive force, yield strength, and Young\u2019s modulus (<jats:italic>r<\/jats:italic>\u2009=\u20090.38, 0.809, 0.293, 0.293, 0.228, 0.318, 0.352, 0.315, and 0.266, respectively, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) and negatively correlated with age and Tb.Sp (<jats:italic>r<\/jats:italic>\u2009=\u2009\u2212\u20090.56 and\u2009\u2212\u20090.38, respectively, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Serum levels of sclerostin and Dkk-1 reflected the levels of sclerostin and Dkk-1 in the bone.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Bone sclerostin and Dkk-1 were positively correlated with BMD in women with PO, and higher levels of bone sclerostin and Dkk-1 might predict better BMD, bone microarchitecture, and bone strength. The potential molecular mechanisms still require further study.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12891-021-04365-8","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T19:02:38Z","timestamp":1621969358000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Bone Sclerostin and Dickkopf-related protein-1 are positively correlated with bone mineral density, bone microarchitecture, and bone strength in postmenopausal osteoporosis"],"prefix":"10.1186","volume":"22","author":[{"given":"Jia","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Aifei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng","family":"Lianfu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Youjia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"issue":"1","key":"4365_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12891-020-03713-4","volume":"21","author":"K J\u00e4ckle","year":"2020","unstructured":"J\u00e4ckle K, Kolb JP, Schilling AF, Schlickewei C, Amling M, Rueger JM, et al. Analysis of low-dose estrogen on callus BMD as measured by pQCT in postmenopausal women. BMC Musculoskelet Disord. 2020;21(1):1.","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"4365_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00223-013-9774-y","volume":"94","author":"T Bellido","year":"2014","unstructured":"Bellido T. Osteocyte-driven bone remodeling. Calcif Tissue Int. 2014;94(1):25\u201334.","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"4365_CR3","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1210\/er.2012-1026","volume":"34","author":"SL Dallas","year":"2013","unstructured":"Dallas SL, Prideaux M, Bonewald LF. The Osteocyte: an endocrine cell \u2026 and more. Endocr Rev. 2013;34(5):658\u201390.","journal-title":"Endocr Rev"},{"issue":"2","key":"4365_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00223-013-9749-z","volume":"93","author":"M Rossini","year":"2013","unstructured":"Rossini M, Gatti D, Adami S. Involvement of WNT\/beta-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int. 2013;93(2):121\u201332.","journal-title":"Calcif Tissue Int"},{"issue":"Pt 7","key":"4365_CR5","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1242\/jcs.02883","volume":"119","author":"GJ Spencer","year":"2006","unstructured":"Spencer GJ, Utting JC, Etheridge SL, Arnett TR, Genever PG. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci. 2006;119(Pt 7):1283\u201396.","journal-title":"J Cell Sci"},{"issue":"5","key":"4365_CR6","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","volume":"8","author":"DA Glass 2nd","year":"2005","unstructured":"Glass DA 2nd, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8(5):751\u201364.","journal-title":"Dev Cell"},{"issue":"27","key":"4365_CR7","doi-asserted-by":"publisher","first-page":"16744","DOI":"10.1074\/jbc.M114.628313","volume":"290","author":"JM Spatz","year":"2015","unstructured":"Spatz JM, Wein MN, Gooi JH, Qu Y, Garr JL, Liu S, et al. The Wnt inhibitor Sclerostin is up-regulated by mechanical unloading in osteocytes in vitro. J Biol Chem. 2015;290(27):16744\u201358.","journal-title":"J Biol Chem"},{"issue":"3","key":"4365_CR8","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1086\/318811","volume":"68","author":"ME Brunkow","year":"2001","unstructured":"Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68(3):577\u201389.","journal-title":"Am J Hum Genet"},{"issue":"23","key":"4365_CR9","doi-asserted-by":"publisher","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","volume":"22","author":"DG Winkler","year":"2003","unstructured":"Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003;22(23):6267\u201376.","journal-title":"EMBO J"},{"issue":"6","key":"4365_CR10","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/jbmr.2423","volume":"30","author":"L Gifre","year":"2015","unstructured":"Gifre L, Vidal J, Carrasco JL, Filella X, Ruiz-Gaspa S, Muxi A, et al. Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study. J Bone Miner Res. 2015;30(6):1014\u201321.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"4365_CR11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00774-015-0687-x","volume":"34","author":"SA Polyzos","year":"2016","unstructured":"Polyzos SA, Anastasilakis AD, Kountouras J, Makras P, Papatheodorou A, Kokkoris P, et al. Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease. J Bone Miner Metab. 2016;34(4):447\u201356.","journal-title":"J Bone Miner Metab"},{"key":"4365_CR12","doi-asserted-by":"crossref","unstructured":"Tanaka S, Matsumoto T. Sclerostin: from bench to bedside. J Bone Miner Metab. 2021;39(3):332\u201340.","DOI":"10.1007\/s00774-020-01176-0"},{"issue":"7","key":"4365_CR13","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1096\/fj.201601280R","volume":"31","author":"V Deepak","year":"2017","unstructured":"Deepak V, Kayastha P, McNamara LM. Estrogen deficiency attenuates fluid flow-induced [Ca(2+)]i oscillations and mechanoresponsiveness of MLO-Y4 osteocytes. FASEB J. 2017;31(7):3027\u201339.","journal-title":"FASEB J"},{"issue":"13","key":"4365_CR14","doi-asserted-by":"publisher","first-page":"9035","DOI":"10.1074\/jbc.M112.405456","volume":"288","author":"GL Galea","year":"2013","unstructured":"Galea GL, Meakin LB, Sugiyama T, Zebda N, Sunters A, Taipaleenmaki H, et al. Estrogen receptor alpha mediates proliferation of osteoblastic cells stimulated by estrogen and mechanical strain, but their acute down-regulation of the Wnt antagonist Sost is mediated by estrogen receptor beta. J Biol Chem. 2013;288(13):9035\u201348.","journal-title":"J Biol Chem"},{"issue":"13\u201314","key":"4365_CR15","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1089\/ten.tea.2014.0585","volume":"21","author":"RY Kim","year":"2015","unstructured":"Kim RY, Yang HJ, Song YM, Kim IS, Hwang SJ. Estrogen modulates bone morphogenetic protein-induced Sclerostin expression through the Wnt signaling pathway. Tissue Eng Part A. 2015;21(13\u201314):2076\u201388.","journal-title":"Tissue Eng Part A"},{"issue":"4","key":"4365_CR16","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1210\/jc.2009-2283","volume":"95","author":"FS Mirza","year":"2010","unstructured":"Mirza FS, Padhi ID, Raisz LG, Lorenzo JA. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab. 2010;95(4):1991\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"4365_CR17","doi-asserted-by":"publisher","first-page":"E81","DOI":"10.1210\/jc.2013-3249","volume":"99","author":"K Fujita","year":"2014","unstructured":"Fujita K, Roforth MM, Demaray S, McGregor U, Kirmani S, McCready LK, et al. Effects of estrogen on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in postmenopausal women. J Clin Endocrinol Metab. 2014;99(1):E81\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"4365_CR18","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.bbrc.2012.06.100","volume":"424","author":"BJ Kim","year":"2012","unstructured":"Kim BJ, Bae SJ, Lee SY, Lee YS, Baek JE, Park SY, et al. TNF-alpha mediates the stimulation of sclerostin expression in an estrogen-deficient condition. Biochem Biophys Res Commun. 2012;424(1):170\u20135.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"4365_CR19","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/jbmr.2351","volume":"30","author":"RR Recker","year":"2015","unstructured":"Recker RR, Benson CT, Matsumoto T, Bolognese MA, Robins DA, Alam J, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015;30(2):216\u201324.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"4365_CR20","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1359\/jbmr.081206","volume":"24","author":"X Li","year":"2009","unstructured":"Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24(4):578\u201388.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"4365_CR21","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412\u201320.","journal-title":"N Engl J Med"},{"key":"4365_CR22","doi-asserted-by":"publisher","first-page":"11505","DOI":"10.1038\/ncomms11505","volume":"7","author":"M Florio","year":"2016","unstructured":"Florio M, Gunasekaran K, Stolina M, Li X, Liu L, Tipton B, et al. A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. Nat Commun. 2016;7:11505.","journal-title":"Nat Commun"},{"issue":"5","key":"4365_CR23","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s00223-015-0093-3","volume":"98","author":"M Rossini","year":"2016","unstructured":"Rossini M, Viapiana O, Idolazzi L, Ghellere F, Fracassi E, Troplini S, et al. Higher level of Dickkopf-1 is associated with low bone mineral density and higher prevalence of vertebral fractures in patients with Ankylosing spondylitis. Calcif Tissue Int. 2016;98(5):438\u201345.","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"4365_CR24","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00404-017-4288-x","volume":"295","author":"MN Kalem","year":"2017","unstructured":"Kalem MN, Kalem Z, Akgun N, Bakirarar B. The relationship between postmenopausal women\u2019s sclerostin levels and their bone density, age, body mass index, hormonal status, and smoking and consumption of coffee and dairy products. Arch Gynecol Obstet. 2017;295(3):785\u201393.","journal-title":"Arch Gynecol Obstet"},{"issue":"9","key":"4365_CR25","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1002\/jbmr.1929","volume":"28","author":"S Thorson","year":"2013","unstructured":"Thorson S, Prasad T, Sheu Y, Danielson ME, Arasu A, Cummings SR, et al. Sclerostin and bone strength in women in their 10th decade of life. J Bone Miner Res. 2013;28(9):2008\u201316.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"4365_CR26","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/j.1365-2265.2011.04315.x","volume":"76","author":"Z Sheng","year":"2012","unstructured":"Sheng Z, Tong D, Ou Y, Zhang H, Zhang Z, Li S, et al. Serum sclerostin levels were positively correlated with fat mass and bone mineral density in central south Chinese postmenopausal women. Clin Endocrinol. 2012;76(6):797\u2013801.","journal-title":"Clin Endocrinol"},{"issue":"2","key":"4365_CR27","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00198-012-1978-x","volume":"24","author":"P Garnero","year":"2012","unstructured":"Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int. 2012;24(2):489\u201394.","journal-title":"Osteoporos Int"},{"issue":"8","key":"4365_CR28","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1002\/jbmr.1888","volume":"28","author":"P Szulc","year":"2013","unstructured":"Szulc P, Boutroy S, Vilayphiou N, Schoppet M, Rauner M, Chapurlat R, et al. Correlates of bone microarchitectural parameters and serum sclerostin levels in men: the STRAMBO study. J Bone Miner Res. 2013;28(8):1760\u201370.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"4365_CR29","doi-asserted-by":"publisher","first-page":"E665","DOI":"10.1210\/jc.2013-2086","volume":"99","author":"J He","year":"2014","unstructured":"He J, Zhang H, Wang C, Zhang Z, Yue H, Hu W, et al. Associations of serum sclerostin and polymorphisms in the SOST gene with bone mineral density and markers of bone metabolism in postmenopausal Chinese women. J Clin Endocrinol Metab. 2014;99(4):E665\u201373.","journal-title":"J Clin Endocrinol Metab"},{"key":"4365_CR30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bone.2016.11.024","volume":"96","author":"MM Weivoda","year":"2017","unstructured":"Weivoda MM, Youssef SJ, Oursler MJ. Sclerostin expression and functions beyond the osteocyte. Bone. 2017;96:45\u201350.","journal-title":"Bone"},{"issue":"2","key":"4365_CR31","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3390\/ijms22020489","volume":"22","author":"N Mart\u00ednez-Gil","year":"2021","unstructured":"Mart\u00ednez-Gil N, Roca-Ayats N, Cozar M, Garcia-Giralt N, Ovejero D, Nogu\u00e9s X, et al. Genetics and genomics of SOST: functional analysis of variants and genomic regulation in Osteoblasts. Int J Mol Sci. 2021;22(2):489.","journal-title":"Int J Mol Sci"},{"key":"4365_CR32","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.bone.2014.03.039","volume":"64","author":"N Okazaki","year":"2014","unstructured":"Okazaki N, Chiba K, Taguchi K, Nango N, Kubota S, Ito M, et al. Trabecular microfractures in the femoral head with osteoporosis: analysis of microcallus formations by synchrotron radiation micro CT. Bone. 2014;64:82\u20137.","journal-title":"Bone"},{"issue":"4","key":"4365_CR33","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.bone.2008.12.022","volume":"44","author":"E Tanck","year":"2009","unstructured":"Tanck E, Bakker AD, Kregting S, Cornelissen B, Klein-Nulend J, Van Rietbergen B. Predictive value of femoral head heterogeneity for fracture risk. Bone. 2009;44(4):590\u20135.","journal-title":"Bone"},{"issue":"4","key":"4365_CR34","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/jbmr.2092","volume":"29","author":"J McColm","year":"2014","unstructured":"McColm J, Hu L, Womack T, Tang CC, Chiang AY. Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res. 2014;29(4):935\u201343.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"4365_CR35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jbmr.173","volume":"26","author":"D Padhi","year":"2011","unstructured":"Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26(1):19\u201326.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"4365_CR36","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1159\/000358303","volume":"60","author":"P Dovjak","year":"2014","unstructured":"Dovjak P, Dorfer S, Foger-Samwald U, Kudlacek S, Marculescu R, Pietschmann P. Serum levels of sclerostin and dickkopf-1: effects of age, gender and fracture status. Gerontology. 2014;60(6):493\u2013501.","journal-title":"Gerontology"},{"key":"4365_CR37","doi-asserted-by":"publisher","first-page":"460210","DOI":"10.1155\/2013\/460210","volume":"2013","author":"SF Ahmed","year":"2013","unstructured":"Ahmed SF, Fouda N, Abbas AA. Serum dickkopf-1 level in postmenopausal females: correlation with bone mineral density and serum biochemical markers. J Osteoporos. 2013;2013:460210.","journal-title":"J Osteoporos"},{"issue":"8","key":"4365_CR38","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/jbmr.396","volume":"26","author":"R Jemtland","year":"2011","unstructured":"Jemtland R, Holden M, Reppe S, Olstad OK, Reinholt FP, Gautvik VT, et al. Molecular disease map of bone characterizing the postmenopausal osteoporosis phenotype. J Bone Miner Res. 2011;26(8):1793\u2013801.","journal-title":"J Bone Miner Res"},{"issue":"12","key":"4365_CR39","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.3390\/ijms20122896","volume":"20","author":"T Ueland","year":"2019","unstructured":"Ueland T, Stilgren L, Bollerslev J. Bone matrix levels of Dickkopf and Sclerostin are positively correlated with bone mass and strength in postmenopausal Osteoporosis. Int J Mol Sci. 2019;20(12):2896.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4365_CR40","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.tem.2010.01.010","volume":"21","author":"SC Manolagas","year":"2010","unstructured":"Manolagas SC, Parfitt AM. What old means to bone. Trends Endocrinol Metab. 2010;21(6):369\u201374.","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"4365_CR41","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s00223-016-0160-4","volume":"99","author":"Y Lim","year":"2016","unstructured":"Lim Y, Kim CH, Lee S-Y, Kim H, Ahn SH, Lee SH, et al. Decreased plasma levels of Sclerostin but not Dickkopf-1 are associated with an increased prevalence of osteoporotic fracture and lower bone mineral density in postmenopausal Korean women. Calcif Tissue Int. 2016;99(4):350\u20139.","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"4365_CR42","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s00198-010-1525-6","volume":"23","author":"SA Polyzos","year":"2012","unstructured":"Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide. Osteoporos Int. 2012;23(3):1171\u20136.","journal-title":"Osteoporos Int"},{"issue":"11","key":"4365_CR43","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1002\/jbmr.1681","volume":"27","author":"D Gatti","year":"2012","unstructured":"Gatti D, Viapiana O, Fracassi E, Idolazzi L, Dartizio C, Povino MR, et al. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. J Bone Miner Res. 2012;27(11):2259\u201363.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"4365_CR44","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.cmet.2007.05.001","volume":"5","author":"S Tatsumi","year":"2007","unstructured":"Tatsumi S, Ishii K, Amizuka N, Li M, Kobayashi T, Kohno K, et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab. 2007;5(6):464\u201375.","journal-title":"Cell Metab"},{"issue":"2","key":"4365_CR45","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.bone.2012.08.121","volume":"54","author":"CA O'Brien","year":"2013","unstructured":"O'Brien CA, Nakashima T, Takayanagi H. Osteocyte control of osteoclastogenesis. Bone. 2013;54(2):258\u201363.","journal-title":"Bone"},{"key":"4365_CR46","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.bone.2014.06.006","volume":"66","author":"J Xiong","year":"2014","unstructured":"Xiong J, Piemontese M, Thostenson JD, Weinstein RS, Manolagas SC, O'Brien CA. Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused by dietary calcium deficiency. Bone. 2014;66:146\u201354.","journal-title":"Bone"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-021-04365-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12891-021-04365-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-021-04365-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T19:02:45Z","timestamp":1621969365000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-021-04365-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4365"],"URL":"https:\/\/doi.org\/10.1186\/s12891-021-04365-8","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,25]]},"assertion":[{"value":"16 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All study procedures were approved by the ethical review board of the Second Affiliated Hospital of Soochow University (approval number: 2017-H-16) and performed in compliance with the Helsinki Declaration. Informed written consent was obtained from all individual participants and is available from the corresponding author upon request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Jia Peng, Zhang Dong, Zhang Hui, Wang Aifei, Deng Lianfu, and Xu Youjia declare that there are no conflicts of interest regarding this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"480"}}